Whole abdomen irradiation in epithelial ovarian cancer - State of the art

Wspolczesna Onkologia

Volumn 13, Issue 4, 2009, Pages 181-190

  Gocheva, Lilia ^a  

^a UNIVERSITY HOSPITAL 'QUEEN GIOVANNA'   (Bulgaria)

Author keywords

Epithelial ovarian cancer; Radiotherapy; State of the art; Whole abdomen irradiation

Indexed keywords

ANTINEOPLASTIC AGENT; AZD 2281; EGEN 001; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 12; OREGOVOMAB; PHOSPHORUS 32; PLATINUM COMPLEX; SARCOLYSIN; UNCLASSIFIED DRUG;

ABDOMINAL RADIOTHERAPY; ADJUVANT THERAPY; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER CONTROL; CANCER GENE THERAPY; CANCER GENETICS; CANCER GRADING; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER RESISTANCE; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; DISEASE FREE SURVIVAL; DOSIMETRY; DRUG TARGETING; ENDOMETRIOID CARCINOMA; GYNECOLOGIC SURGERY; HISTOPATHOLOGY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MONOTHERAPY; NONVIRAL GENE THERAPY; OVARY CANCER; OVARY CARCINOMA; OVERALL SURVIVAL; PATIENT CARE PLANNING; PATIENT SAFETY; PROGNOSIS; PROGRESSION FREE SURVIVAL; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RADIATION RESPONSE; RECURRENCE RISK; REVIEW; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT DURATION; TREATMENT INDICATION;

EID: 70350735997     PISSN: 14282526     EISSN: 14282526     Source Type: Journal    
DOI: None     Document Type: Review

References (112)

1. McGuire WP, Rowinsky EK. Old drugs revisited, new drugs, and experimental approaches on ovarian cancer therapy. Semin Oncol 1991; 18: 255.
2. McGuire WP, Hoskins WJ, Brady M, et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 1995; 13: 1589-1599.
3. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl Med 1996; 334: 1-6. (Pubitemid 26012496)
4. McGuire WP, Hoskins WJ, Brady MF, et al. A phase III trial of dose-intense vs. standard dose cisplatin and cytoxan in advanced ovarian cancer. Proc Am Soc Clin Oncol 1992; 11: A718.
5. Makatsoris T, Seiden MS. High-dose therapy for ovarian carcinoma. Oncologist 1997; 2: 330-339.
6. Piccart MJ, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000; 92: 699-708.
7. Kojs Z, Glinski B, Reinfuss M, Pudelek J, Urbanski K, Kowalska T, Kulpa J. Results of a randomized prospective trial comparing postoperative abdominopelvic radiotherapy with postoperative chemotherapy in early ovarian cancer Cancer Radiother 2001; 5: 5-11.
8. Cmelak A, Kapp D. Long-term survival with whole abdomino-pelvic irradiation in platinum-refractory persistent or recurrent ovarian cancer. Gynecol Oncol 1997; 65: 453-460. (Pubitemid 27255988)
9. Dembo AJ, Bush RS. Choice of postoperative therapy based on prognostic factors. Int J Rad Oncol Biol Phys 1982; 8: 893-897.
10. Dembo AJ. Abdomino-pelvic radiotherapy in ovarian cancer: a 10 year experience. Cancer 1984; 55: 2285-2290.
11. Dembo AJ, Davy M, Stenvig AE. Prognostic factors in patients with stage I epithelial ovarian cancer. Obstet Gynecol 1990; 75: 263-273. (Pubitemid 20062245)
12. Carey MS, Dembo AJ, Simm JE, Fyles AW, Treger T, Bush RS. Testing the validity of a prognostic classification in patients with surgically optimal ovarian carcinoma: a 15-year review. Int J Gynecol Cancer 1993; 3: 24-35. (Pubitemid 23207593)
13. Dinniwell R, Lock M, Pintilie M, et al. Consolidative abdominopelvic radiotherapy after surgery and carboplatin/paclitaxel chemotherapy for epithelial ovarian cancer. Int J Radiat Oncol Biol Phys 2005; 62: 104-110. (Pubitemid 40591930)
14. Young RC, Walton LA, Ellenberg SS, et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer: Results of the prospective randomized trials. N Engl J Med 1990; 322: 1021-1027.
15. Baak JP, Schipper NW, Wisse-Brekelmans EC, Ceelen T, Bosman FT, van Geuns H, Wils J. The prognostic value of morphometrical features and cellular DNA content in FIGO I ovarian cancer patients. Br J Cancer 1988; 57: 503-508. (Pubitemid 18156303)
16. Friedlander ML, Headley DH, Swanson C, Russell P. Prediction of long term survivals by flow cytometric analysis of DNA content in patients with advanced ovarian cancer. J Clin Oncol 1988; 6: 282-290. (Pubitemid 18065932)
17. Wong R, Wong R, Milosevic M, et al. Treatment of early epithelial ovarian cancer with chemotherapy and abdominopelvic radiotherapy: results of a prospective treatment protocol. Int J Rad Oncol Biol Phys 1999; 45: 657-665. (Pubitemid 29462647)
18. Klaassen D, Shelley W, Starreveld A, et al. Early stage ovarian cancer: a randomized clinical trial comparing whole abdominal radiotherapy, melphalan, and intraperitoneal chromic phosphate: a National Cancer Institute of Canada Clinical Trials Group report. J Clin Oncol 1988; 6: 1254-1263. (Pubitemid 18196803)
19. Jenison EL, Montag AG, Griffiths CT, Welch WR, Lavin PT, Greer J, Knapp RC. Clear cell adenocarcinoma of the ovary: a clinical analysis and comparison with serous adenocarcinoma. Gynecol Oncol 1989; 32: 65-71 (Pubitemid 19029870)
20. Thomas L, Pigneux J, Chauvergne J, Stöckle E, Bussi? res E, Chemin A, Toulouse C. Abdominopelvic radiation therapy in the treatment of ovarian carcinoma. Study of a continuous series of 167 patients. Bull Cancer Radiother 1994; 81: 23-31.
21. Kapp KS, Kapp DS, Poschauko J, Stücklschweiger GF, Hackl A, Pickel H, Petru E, Winter R. The prognostic significance of peritoneal seeding and size of postsurgical residual in patients with stage III epithelial ovarian cancer treated with surgery, chemotherapy, and high-dose radiotherapy. Gynecol Oncol 1999; 74: 400-407. (Pubitemid 29439880)
22. Mychalchak BR, Fucks Z. The current role of radiotherapy in the management of ovarian cancer. Hematol Oncol Clin North Am 1992; 6: 895-913.
23. Hsieh SS, Malerczyk C, Aigner A, Czubayko F. Reversal of Her-2 overexpression renders human ovarian cancer cells highly resistant to taxol. Toxicology 2000; 44: 221-228. (Pubitemid 30201640)
24. Skirnisdóttir I, Sorbe B, Seidal T. The growth factor receptors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma. Int J Gynecol Cancer 2001; 11: 119-129. (Pubitemid 32381660)
25. Dembo AJ. Epithelial ovarian cancer: the role of radiotherapy. Int J Rad Oncol Biol Phys 1992; 22: 835-845.
26. Einhorn N, von Hamos K, Hindmarsh T, Lagergren C, Lundell M, Mellstedt H, Tjernberg B. Radiation in ovarian carcinoma: evaluation of a six-field technique. Radiother Oncol 1986; 7: 125-131. (Pubitemid 17180964)
27. Einhorn N, Lundell M, Nilsson B, Ragnarsson-Olding B, Sjövall K. Is there place for radiotherapy in the treatment of advanced ovarian cancer? Radiother Oncol 1999; 53: 213-218.
28. Martinez A, Schray MF, Howes AE, Bagshaw MA. Postoperative radiation therapy for epithelial ovarian cancer: the curative role based on a 24 year experience. J Clin Oncol 1985; 3: 901-910. (Pubitemid 15028559)
29. Kuten A, Stein M, Steiner M, Rubinov R, Epelbaum R, Cohen Y. Whole abdominal irradiation following chemotherapy in advanced ovarian carcinoma. Int J Rad Oncol Biol Phys 1988; 14: 273. (Pubitemid 18042188)
30. Calkins AR, Rosenshein NB, Fox MG, Order SE. Delayed split whole abdominal irradiation in the combined modality treatment of ovarian cancer. Int J Rad Oncol Biol Phys 1991; 20: 661-665.
31. Thomas L, Pigneux J, Chauvergne J, Stöckle E, Bussiéres E, Chemin A, Toulouse C. Evaluation of whole abdominal irradiation in ovarian carcinoma with a four orthogonal field technique. Int J Rad Oncol Biol Phys 1994; 30: 1083-1090. (Pubitemid 24362517)
32. Hong L, Alektiar K, Chui C, et al. IMRT of large fields: whole-abdomen irradiation. Int J Rad Oncol Biol Phys 2002; 54: 278-289. (Pubitemid 34899677)
33. Duthoy W, De Gersem W, Vergote K, et al. Whole abdomino-pelvic radiotherapy (WAPRT) using intensity-modulated arc therapy (IMAT): first clinical experience. Int J Rad Oncol Biol Phys 2003; 57: 1019-1032. (Pubitemid 37324120)
34. Rochet N, Sterzing F, Jensen A, et al. Helical tomotherapy as a new treatment technique for whole abdominal irradiation. Strahlenther Oncol 2008; 184: 145-149.
35. Kong JS, Peters LJ, Wharton JT, et al. Hyperfractionated split course whole abdominal radiotherapy for ovarian carcinoma: tolerance and toxicity. Int J Rad Oncol Biol Phys 1988; 14: 737-743.
36. Eifel PJ, Gershenson DM, Delclos L, Wharton JT, Peters LJ. Twice-daily, split-course abdominopelvic radiation therapy after chemotherapy and positive second-look laparotomy for epithelial ovarian carcinoma. Int J Rad Oncol Biol Phys 1991; 21: 1013-1018.
37. Fein DA, Morgan LS, Marcus RB Jr, Mendenhall WM, Sombeck MD, Freeman DE, Million RR. Stage III ovarian carcinoma: an analysis of treatment results and complications following hyperfractionationated abdomino-pelvic irradiation for salvage. Int J Rad Oncol Biol Phys 1994; 29: 169-176.
38. Morgan L, Chafe W, Mendenhall W, Marcus R. Hyperfractionation of whole-abdomen radiation therapy: salvage treatment of persistent ovarian carcinoma following chemotherapy. Gynecol Oncol 1988; 31: 122-136. (Pubitemid 18221343)
39. Faul C, Gerszten K, Edwards R, Land S, D'Angelo G, Kelley J 3rd, Price F. A phase I/II study of hypofractionated whole abdominal radiation therapy in patients with chemoresistant ovarian carcinoma: Karnofsky score determines treatment outcome. Int J Rad Oncol Biol Phys 2000; 47: 749-754. (Pubitemid 30317495)
40. Fyles AW, Thomas GM, Pintilie M, Ackerman I, Levin W. A randomized study of two doses of abdominopelvic radiation therapy for patients with optimally debulked Stage I, II, and III ovarian cancer. Int J Rad Oncol Biol Phys 1998; 41: 543-549. (Pubitemid 28275082)
41. Firat S, Murray K, Erickson B. High-dose whole abdominal and pelvic irradiation for treatment of ovarian carcinoma: long-term toxicity and outcomes. Int J Rad Oncol Biol Phys 2003; 57: 201-207. (Pubitemid 36959757)
42. Fyles A, Dembo A, Bush R, et al. Analysis of complications in patients treated with abdomino-pelvic radiation therapy for ovarian carcinoma. Int J Rad Oncol Biol Phys 1992; 22: 847-851.
43. Schray M, Martinez A, Howes A. Toxicity of open-field whole abdominal irradiation as primary postoperative treatment in gynecologic malignancy. Int J Rad Oncol Biol Phys 1989; 16: 397-403. (Pubitemid 19077205)
44. Hruby G, Bull CA, Langlands AO, Gebski V. WART revisited: the treatment of epithelial ovarian cancer by whole abdominal radiotherapy. Australas Radiol 1997; 41: 276-280. (Pubitemid 27360216)
45. Quétin P, Marchal C, Hoffstetter S, Cutuli B, Beckendorf V, Lapeyre M, Peiffert D, Bey P. Tolerance and role of irradiation in the treatment of epithelial cancer of the ovary. Cancer Radiother 1998; 2: 366-374.
46. Thomas GM, Dembo AJ. Integrating radiation therapy into the management of ovarian cancer. Cancer 1993; 71: 1710-1718. (Pubitemid 23056095)
47. Irwin C, Fyles A, Wong CS, Cheung CM, Zhu Y. Late renal function following whole abdominal irradiation. Radiother Oncol 1996; 38: 257-261. (Pubitemid 26079442)
48. Schneider DP, Marti HP, Von Briel C, Frey FJ, Greiner RH. Long-term evolution of renal function in patients with ovarian cancer after whole abdominal irradiation with or without preceding cisplatin. Ann Oncol 1999; 10: 677-683. (Pubitemid 29342373)
49. Lentz S, Schray M, Wilson T. Chylous ascites after whole-abdomen irradiation for gynecologic malignancy. Int J Rad Oncol Biol Phys 1990; 19: 435-438. (Pubitemid 20299038)
50. Abe H, Nakamura M, Takahashi S, Maruoka S, Ogawa Y, Sakamoto K Radiation-induced insufficiency fractures of the pelvis: evaluation with 99mTc-methylene diphosphonate scintigraphy. Am J Roentgenol 1992; 158: 599-602.
51. Peh WC, Khong PL, Sham JS, Ho WY, Yeung HW. Sacral and pubic insufficiency fractures after irradiation of gynaecological malignancies. Clin Oncol (R Coll Radiol) 1995; 7: 117-122.
52. Tai P, Hammond A, Dyk JV, Stitt L, Tonita J, Coad T, Radwan J. Pelvic fractures following irradiation of endometrial and vaginal cancers - a case series and review of literature. Radiother Oncol 2000; 56: 23-28. (Pubitemid 30408382)
53. Sedlacek TV, Spyropoulus P, Cifaldi R, Glassburn J, Fisher S. Whole-abdomen radiation as salvage treatment for epithelial ovarian carcinoma. Cancer J Sci Am 1997; 3: 358-363. (Pubitemid 28007432)
54. Fyles AW, Manchul L, Levin W, Robertson JM, Sturgeon J, Tsuji D. Effect of filgrastim (G-CSF) during chemotherapy and abdomino-pelvic radiation therapy in patients with ovarian carcinoma. Int J Rad Oncol Biol Phys 1998; 41: 843-847. (Pubitemid 28285963)
55. Travis LB, Curtis RE, Boice JD Jr, Platz CE, Hankey BF, Fraumeni JF Jr. Second malignant neoplasm among long-term survivors of ovarian cancer. Cancer Res 1996; 56: 1564-1570. (Pubitemid 26104020)
56. Kaldor JM, Day NE, Kittelmann B, et al. Bladder tumours following chemotherapy and radiotherapy for ovarian cancer: a case-control study. Int J Cancer 1995; 63: 1-6.
57. Dent SF, Klaassen D, Pater JL, Zee B, Whitehead M. Second primary malignancies following the treatment of early stage ovarian cancer: update of a study by the National Cancer Institute of Canada-Clinical Trials Group (NCIC-CTG). Ann Oncol 2000; 11: 65-68. (Pubitemid 30084581)
58. Sevelda P, Vavra N, Schemper M, Salzer H. Prognostic factors for survival in stage I epithelial ovarian cancer. Cancer 1990; 65: 2349-2352.
59. Benjamin I, Rubin SC. Management of early stage epithelial ovarian cancer. Obstet Gynecol Clin North Am 1994; 21: 107-119. (Pubitemid 24100778)
60. Sainz de la Cuesta R, Goff BA, Fuller AF Jr, Nikrui N, Eichhorn JH, Rice LW. Prognostic importance of intraoperative rupture of malignant epithelial ovarian neoplasms. Obstet Gynecol 1994; 84: 1-7. (Pubitemid 24202946)
61. Skirnisdottir I, Nordqvist S, Sorbe B. Is adjuvant radiotherapy in early stages (FIGO I-II) of epithelial ovarian cancer a treatment of the past? Oncol Rep 2005; 14: 521-529.
62. Brady LW, Markoe AM, Micaily B, Damsker JI, Karlsson UL, Amendola BE. Clinical treatment planning in gynecologic cancer. Front Radiat Ther Oncol 1987; 21: 302-332.
63. Wong R, Milosevic M, Sturgeon J, et al. Treatment of early epithelial ovarian cancer with chemotherapy and abdomino-pelvic radiotherapy: results of a prospective treatment protocol. Int J Rad Oncol Biol Phys 1990; 45: 657-665.
64. Hacker C, Pejovic-Lenfaut M, George H, et al. Whole-abdominal irradiation following chemotherapy in patients with minimal residual disease as second-look surgical reassessment for ovarian carcinoma. Gynecol Oncol 1985; 20: 271-280.
65. Coltart RS, Nethersell A, Brown C. A pilot study of high dose abdomino-pelvic radiotherapy following surgery and chemotherapy for stage III epithelial carcinoma of the ovary. Gynecol Oncol 1986; 23: 105-110. (Pubitemid 16133444)
66. Reid GC, Roberts JA, Hopkins MP, Schoeppel SL, Perez-Tamayo C, Drescher C, Chamberlain D, Morley GW. Primary treatment of stage III ovarian carcinoma with sequential chemotherapy and whole abdominal radiation therapy. Gynecol Oncol 1993; 49: 333-338. (Pubitemid 23191206)
67. Lindner H, Willich H, Atzinger A. Primary adjuvant whole-abdominal irradiation in ovarian carcinoma. Int J Rad Oncol Biol Phys 1990; 19: 1203-1206.
68. Hepp R, Baeza MR, Olfos P, Suarez E. Adjuvant radiotherapy in epithelial cancer of the ovary. Int J Rad Oncol Biol Phys 2002; 53: 360-365.
69. Pietrzak K, Sablinska B, Zielinski J. Clinical analysis and evaluation of the results of adjuvant treatment (radiotherapy and chemotherapy) in ovarian carcinoma. Eur J Gynecol Oncol 1993; 14: 133-139. (Pubitemid 24052687)
70. Chiara S, Conte P, Franzone P, et al. High-risk early-stage ovarian cancer. Randomized clinical trial comparing cisplatin plus cyclophosphamide versus whole abdominal radiotherapy. Amer J Clin Oncol 1994; 17: 72-76. (Pubitemid 24062739)
71. Reddy S, Lee MS, Yordan E, Graham J, Sarin P, Hendrickson FR. Salvage whole abdomen radiation therapy: its role in ovarian cancer. Int J Rad Oncol Biol Phys 1993; 27: 879-884. (Pubitemid 2013260)
72. Homesley HD, Scarantino CW, Muss HB, Welander CE. Concurrent chemotherapy and single high-dose plus whole abdomino-pelvic radiation for persistent ovarian carcinoma. Gynecol Oncol 1989; 34: 170-174.
73. Schray MF, Martinez A, Howes AE, Podratz KC, Ballon SC, Malkasian GD Jr, Sikic BI. Advanced epithelial ovarian cancer: salvage whole abdominal irradiation for patients with recurrent or persistent disease after combination chemotherapy. J Clin Oncol 1988; 6: 1433-1439. (Pubitemid 19089032)
74. Kersh CR, Randall ME, Constable WC, Hahn SS, Taylor PT, Krebs HB, Goplerud DR. Whole abdominal radiotherapy following cytoreductive surgery and chemotherapy in ovarian carcinoma. Gynecol Oncol 1988; 31: 113-120. (Pubitemid 18221342)
75. Rosen EM, Goldberg ID, Rose C, Come S, Goldstein M, Simon L, Botnick LE. Sequential multi-agent chemotherapy and whole-abdominal irradiation for stage III ovarian carcinoma. Radiother Oncol 1986; 7: 223-232. (Pubitemid 17225775)
76. Bolis G, Zanaboni F, Vanoli P, Russo A, Franchi M, Scarfone G, Pecorelli S. The impact of whole-abdomen radiotherapy on survival in advanced ovarian cancer patients with minimal residual disease after chemotherapy. Gynecol Oncol 1990; 39: 150-154. (Pubitemid 20372403)
77. Fucks Z, Rizel S, Biran S. Chemotherapeutic and surgical induction of pathological complete remission and whole-abdominal irradiation for consolidation does not enhance the cure of stage III ovarian carcinoma. J Clin Oncol 1988; 6: 509-516. (Pubitemid 18090700)
78. Haie C, Pejovic-Lenfant MH, George M, Michel G, Gerbaulet A, Prade M, Chassagne D. Whole-abdominal irradiation following chemotherapy in patients with minimal residual disease after second look surgery in ovarian carcinoma. Int J Rad Oncol Biol Phys 1989; 17: 15-19. (Pubitemid 19173233)
79. Kucera PR, Berman ML, Treadwell P, Sheets EE, Micha JP, Rettenmaier MA, Colman M, DiSaia PJ. Whole-abdominal radiotherapy for patients with minimal residual epithelial ovarian cancer. Gynecol Oncol 1990; 36: 338-342. (Pubitemid 20116905)
80. Rothenberg ML, Ozols RF, Glatstein E, Steinberg SM, Reed E, Young RC. Dose-intensive induction therapy with cyclophosphamide, cisplatin, and consolidative abdominal radiation in advanced-stage epithelial ovarian cancer. J Clin Oncol 1992; 10: 727-734.
81. Sheng X, Sun J, Zhou C. Evaluation of radiotherapy for stage I ovarian carcinoma. Chung Hua Ghung Liu Tsa Chih 1996; 18: 314-316.
82. Goldhirsch A, Greiner R, Dreher D, et al. Treatment of advanced ovarian cancer with surgery, chemotherapy, and consolidation of response by whole-abdominal radiotherapy. Cancer 1988; 62: 40-47.
83. Sorbe B, Trope C, Nordal R, et al. Chemotherapy versus radiotherapy as consolidation treatment of ovarian carcinoma, stage III, at complete surgical remission after induction chemotherapy. On behalf of the Swedish-Norwegian Ovarian Cancer Study Group, ASCO 96.
84. Sorbe B; Swedish-Norgewian Ovarian Cancer Study Group. Consolidation treatment of advanced (FIGO stage III) ovarian carcinoma in complete surgical remission after induction chemotherapy: a randomized, controlled, clinical trial comparing whole abdominal radiotherapy, chemotherapy, and no further treatment. Int J Gynecol Cancer 2003; 13: 278-286.
85. Pickel H, Lahousen M, Petru E, Stettner H, Hackl A, Kapp K, Winter R. Consolidation radiotherapy after carboplatin-based chemotherapy in radically operated advanced ovarian cancer. Gynecol Oncol 1999; 72: 215-219.
86. Goldberg H, Stein ME, Steiner M, Sprecher E, Beck D, Kuten A. Consolidation radiation therapy following cytoreductive surgery, chemotherapy and second-look laparotomy for epithelial ovarian carcinoma: long-term follow-up. Tumori 2001; 87: 248-251. (Pubitemid 32928844)
87. Hacker NF, Berek JS, Burnison CM, Heintz PM, Juillard GJ, Lagasse LD. Whole-abdominal radiation as salvage therapy for epithelial ovarian cancer. Obstet Gynecol 1985; 65: 60-66. (Pubitemid 15187630)
88. Reinfus M, Kojs Z, Skolyszewsky J. External beam radiotherapy in the management of ovarian cancer. Radiother Oncol 1992; 46: 226-229.
89. Solomon HJ, Atkinson KH, Coppleson JV, et al. Ovarian carcinoma: abdomino-pelvic irradiation following reexploration. Gynecol Oncol 1988; 31: 396-401. (Pubitemid 18273548)
90. Stephenson JA, Buchlier DA. Abdomino-pelvic irradiation for persistent advanced ovarian carcinoma. Int J Rad Oncol Biol Phys 1989; 51: 385-388. (Pubitemid 19203088)
91. Reddy SR, Hartsell W, Graham J, et al. Whole-abdominal radiation therapy in ovarian carcinoma; its role as a salvage therapeutic modality. Gynecol Oncol 1989; 35: 307-313. (Pubitemid 20025892)
92. Cardenes H, Randall ME. Integrating radiation therapy in the curative management of ovarian cancer: current issues and future directions. Semin Radiat Oncol 2000; 10: 61-70. (Pubitemid 30044150)
93. Corn BW, Lanciano RM, Boente M, Hunter WM, Ladazack J, Ozols RF. Recurrent ovarian cancer-effective radiotherapeutic palliation after chemotherapy failure. Cancer 1994; 74: 2979-2983. (Pubitemid 24361084)
94. Gelblum D, Mychalczak B, Almadrones L, Spriggs D, Barakat R. Palliative benefit of external-beam radiation in the management of platinum refractory epithelial ovarian carcinoma. Gynecol Oncol 1998; 69: 36-41. (Pubitemid 28201669)
95. Firat S, Erickson B. Selective irradiation for the treatment of recurrent ovarian carcinoma involving the vagina or rectum. Gynecol Oncol 2001; 80: 213: 220. (Pubitemid 32158461)
96. Tinger A, Waldron T, Peluso N, et al. Affective palliative radiation therapy in advanced and recurrent ovarian carcinoma. Int J Rad Oncol Biol Phys 2001; 51: 1256-1263. (Pubitemid 33116319)
97. Albuquerque KV, Singla R, Potkul RK, Smith DM, Creech S, Lo S, Emami B. Impact of tumor volume-directed involved field radiation therapy integrated in the management of recurrent ovarian cancer. Gynecol Oncol 2005; 96: 701-704. (Pubitemid 40255489)
98. Colombo A, on behalf of the ICON Collaborators, MRC Clin Trial Unit. Randomized trial of paclitaxel (PTX) and carboplatin (CBDCA) versus a control arm of carboplatin or CAP cyclophosphamide, doxorubicin, cisplatin): The third International Collaborative Ovarian neoplasm study (ICONSo. Proc ASCO) 2000; 19: 1500.
99. Weberpals J, Clark-Knowles K, O'Brien A, et al. The evaluation of BRACAR1 and ERCC1 expression as predictors of platinum response in ovarian cancer. J Clin Oncol 2008 ASCO, 26; 15S: 5587.
100. Fong P, Boss D, Carden C, et al. AZD2281 (KU-0059436), a PARP (polyADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: Results from a phase I study. J Clin Oncol 2008 ASCO, 26; 15S: 5510.
101. Berek J, Taylor P, McQurie, et al. Evaluation of maintenance mono-immunotherapy to improve outcomes in advanced ovarian cancer (OV CA). J Clin Oncol 2008 ASCO, 26; 15S: 5507.
102. Han E, Burger R, Darcy K, et al. Relationship between angiogenic markers and clinicopathologic factors/outcome in GOG-170D, a phase II trial of bevacizumab (Bev) in recurrent or persistent epithelial ovarian cancer (EOC) and primary peritoneal cancer (PPC). J Clin Oncol 2008 ASCO, 26; 15S: 5577.
103. Kendrick J, Matthews K, Straughn J, et al. A phase I trial of intraperitoneal EGEN-001, a novel IL-12 gene therapeutic, administered alone or in combination with chemotherapy in patients with recurrent ovarian cancer. J Clin Oncol 2008 ASCO, 26; 15S: 5572.
104. Paterson R, Tod M, Russel M. The results of radium and X-ray therapy in malignant disease. Edinburgh: E&S Livingstone Ltd; 1950.
105. Dembo AJ, Bush RS, Beale FA, Bean HA, Pringle JF, Sturgeon J, Reid JG. Ovarian carcinoma: improved survival following abdomino-pelvic irradiation in patients with a complete pelvic operation. Am J Obstet Gynecol 1979; 134: 793-800
106. Hoskins PJ, Swenerton KD, Wong F, Manji MF, McMurtrie EM, Le N, Pike J. Platinum plus cyclophosphamide plus radiotherapy is superior to platinum alone in "high-risk" epithelial ovarian cancer (residual negative and either stage I or II, grades 3, or stage III, any grade). Int J Gynecol Cancer 1995; 5: 134-142.
107. Petit T, Velten M, d'Hombres A, et al. Long-term survival of 106 stage III ovarian cancer patients with minimal residual disease after second-look laparotomy and consolidation radiotherapy. Gynecol Oncol 2007; 104: 104-108.
108. MacGibbon A, Bucci J, MacLeod C, Solomon J, Dalrymple C, Firth I, Carter J. Whole abdominal radiotherapy following second-look laparotomy for ovarian carcinoma. Gynecol Oncol 1999; 75: 62-67. (Pubitemid 29477803)
109. Dowdy SC, Metzinger DS, Gebhart JB, Srivatsa P, Haddock MG, Suman VJ, Podratz KC. Salvage whole-abdominal radiation therapy after second-look laparotomy or secondary debulking surgery in patients with ovarian cancer. Gynecol Oncol 2005; 96: 389-394. (Pubitemid 40127139)
110. Dowdy SC, Constantinou CL, Hartmann LC, Keeney GL, Suman VJ, Hillman DW, Podratz KC. Long-term follow-up of women with ovarian cancer after positive second-look laparotomy. Gynecol Oncol 2003; 91: 563-568. (Pubitemid 38388151)
111. Sorbe B. Consolidation treatment of advanced ovarian carcinoma with radiotherapy after induction chemotherapy. Int J Gynecol Cancer 2003; 13: 192-195. (Pubitemid 38228764)
112. Whelan TJ, Dembo AJ, Bush RS, et al. Complications of whole abdominal and pelvic radiotherapy following chemotherapy for advanced ovarian cancer. Int J Rad Oncol Biol Phys 1992; 22: 853-858.